Trial Profile
Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 18 Nov 2015 New trial record